Products for Research Use Only
RegisterLogin

Idarubicin

CAT: 0804-HY-17381A-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-17381A-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Idarubicin is an orally active and potent anthracycline antileukemic agent. Idarubicin inhibits the topoisomerase II interfering with the replication of DNA and RNA transcription. Idarubicin shows induction of DNA damage. Idarubicin inhibits DNA synthesis and of c-myc expression. Idarubicin inhibits the growth of bacteria and yeasts[1][2][3][4][5].
CAS Number
58957-92-9
Product Name Alternative
4-Demethoxydaunorubicin
UNSPSC
12352005
Hazard Statement
H302, H312, H332
Target
Antibiotic; Autophagy; Bacterial; c-Myc; DNA/RNA Synthesis; Fungal; Topoisomerase
Type
Reference compound
Related Pathways
Anti-infection; Apoptosis; Autophagy; Cell Cycle/DNA Damage
Applications
COVID-19-anti-virus
Field of Research
Cancer; Infection
Assay Protocol
https://www.medchemexpress.com/idarubicin.html
Purity
99.89
Solubility
10 mM in DMSO
Smiles
OC(C(C(C1=CC=CC=C21)=O)=C3C2=O)=C4[C@H](C[C@@](C(C)=O)(O)CC4=C3O)O[C@@](O[C@@H](C)[C@H]5O)([H])C[C@@H]5N
Molecular Formula
C26H27NO9
Molecular Weight
497.49
Precautions
H302, H312, H332
References & Citations
[1]Orlandi P, et al. Idarubicin and idarubicinol effects on breast cancer multicellular spheroids. J Chemother. 2005 Dec;17 (6) :663-7.|[2]Robert J. Clinical pharmacokinetics of idarubicin. Clin Pharmacokinet. 1993 Apr;24 (4) :275-88.|[3]Siegsmund MJ, et al. Enhanced in vitro cytotoxicity of idarubicin compared to epirubicin and doxorubicin in rat prostate carcinoma cells. Eur Urol. 1997;31 (3) :365-70.|[4]Gewirtz DA, et al. Induction of DNA damage, inhibition of DNA synthesis and suppression of c-myc expression by the anthracycline analog, idarubicin (4-demethoxy-daunorubicin) in the MCF-7 breast tumor cell line. Cancer Chemother Pharmacol. 1998;41 (5) :361-|[5]Kinnunen U, et al. Idarubicin inhibits the growth of bacteria and yeasts in an automated blood culture system. Eur J Clin Microbiol Infect Dis. 2009 Mar;28 (3) :301-3.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture and light)
Scientific Category
Reference compound1
Clinical Information
Launched
Isoform
Topo II
Citation 01
Cancer Cell Int. 2024 Dec 26;24 (1) :430.|Mol Carcinog. 2023 Oct;62 (10) :1546-1562.|Anal Chem. 2022 Oct 4;94 (39) :13623-13630.|bioRxiv. 2023 Jan 13.|Cancer Lett. 2019 Oct 1:461:31-43.|Cell Rep Med. 2025 Apr 2:102053.|Exp Cell Res. 2020 Aug 1;393 (1) :112054.|iScience. 2024 Jun 8;27 (7) :110221.|J Mol Med (Berl) . 2019 Aug;97 (8) :1183-1193.|J Virol. 2019 May 15;93 (11) :e02230-18.|Nat Cell Biol. 2024 Aug;26 (8) :1346-1358.|Nat Commun. 2020 Apr 14;11 (1) :1792.|Nucleic Acids Res. 2018 Apr 20;46 (7) :3284-3297.|University of Paris. 2022 Sep 19.|Viruses. 2020 Jun 10;12 (6) :628.

Related Products

CatalogName
HY-W768541Idarubicinol-d4 (Mixture of Diastereomers)

Alternative Products

CatalogName
GTR19188415-01Idarubicin
A2476-5Idarubicin HCl
I051-5x10MGIdarubicin Hydrochloride
ALX-380-260-M005Idarubicin . hydrochloride

Popular Products